Lipigon Pharmaceuticals Investor Relations Material

Lipigon Pharmaceuticals AB specializes in developing therapeutics for lipid-related disorders. The company focuses on creating drugs with unique mechanisms of action to treat diseases resulting from disruptions in the body's lipid metabolism. Their projects include treatments for severe hypertriglyceridemia, familial chylomicronemia syndrome, lipodystrophy, dyslipidemia, and acute respiratory distress syndrome. The company is headquartered in Umeå, Sweden, and its shares are listed on the OMX Stockholm.